Beauty Health Future Growth
Future criteria checks 3/6
Beauty Health is forecast to grow earnings and revenue by 20.5% and 5.1% per annum respectively while EPS is expected to grow by 23.7% per annum.
Key information
20.5%
Earnings growth rate
23.7%
EPS growth rate
| Personal Products earnings growth | 25.9% |
| Revenue growth rate | 5.1% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
Health Check: How Prudently Does Beauty Health (NASDAQ:SKIN) Use Debt?
Oct 18
Positive Sentiment Still Eludes The Beauty Health Company (NASDAQ:SKIN) Following 33% Share Price Slump
Aug 06Is There Now An Opportunity In The Beauty Health Company (NASDAQ:SKIN)?
Jul 16Not Many Are Piling Into The Beauty Health Company (NASDAQ:SKIN) Stock Yet As It Plummets 28%
Jun 14Calculating The Fair Value Of The Beauty Health Company (NASDAQ:SKIN)
May 30The Beauty Health Company (NASDAQ:SKIN) Stock Rockets 31% But Many Are Still Ignoring The Company
Feb 16The Beauty Health Company's (NASDAQ:SKIN) Share Price Matching Investor Opinion
Jun 19Is The Beauty Health Company (NASDAQ:SKIN) Trading At A 39% Discount?
May 28At US$13.26, Is The Beauty Health Company (NASDAQ:SKIN) Worth Looking At Closely?
Apr 04Beauty Health's (NASDAQ:SKIN) Earnings Are Of Questionable Quality
Mar 08What Is The Beauty Health Company's (NASDAQ:SKIN) Share Price Doing?
Jan 01An Intrinsic Calculation For The Beauty Health Company (NASDAQ:SKIN) Suggests It's 24% Undervalued
Dec 05The Beauty Health Company: A Compelling Mid To Long-Term Growth Story
Oct 12Beauty-Health Company announces $200M buyback program
Sep 27The Beauty Health Q2 2022 Earnings Preview
Aug 08The Beauty Health Company: Not Looking The Best
Jul 30Beauty Health: Skincare Today And Alpha Tomorrow
May 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 378 | -23 | -24 | -30 | 4 |
| 12/31/2025 | 339 | -33 | 4 | 9 | 9 |
| 12/31/2024 | 328 | -34 | -6 | -7 | 8 |
| 9/30/2024 | 348 | -28 | -14 | -6 | N/A |
| 6/30/2024 | 366 | -84 | -8 | 2 | N/A |
| 3/31/2024 | 393 | -81 | 6 | 18 | N/A |
| 12/31/2023 | 398 | -100 | -10 | 22 | N/A |
| 9/30/2023 | 399 | -84 | -11 | 22 | N/A |
| 6/30/2023 | 391 | -10 | -63 | -28 | N/A |
| 3/31/2023 | 377 | -7 | -118 | -81 | N/A |
| 12/31/2022 | 366 | 44 | -125 | -107 | N/A |
| 9/30/2022 | 346 | 20 | -123 | -98 | N/A |
| 6/30/2022 | 325 | -195 | -85 | -66 | N/A |
| 3/31/2022 | 288 | -340 | -86 | -68 | N/A |
| 12/31/2021 | 260 | -379 | -44 | -28 | N/A |
| 9/30/2021 | 220 | -365 | -40 | -32 | N/A |
| 6/30/2021 | 186 | -152 | -40 | -33 | N/A |
| 3/31/2021 | 134 | -23 | N/A | N/A | N/A |
| 12/31/2020 | 119 | -29 | -16 | -12 | N/A |
| 9/30/2020 | 131 | -19 | -12 | -3 | N/A |
| 12/31/2019 | 167 | -2 | -9 | 2 | N/A |
| 12/31/2018 | 112 | -91 | -9 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SKIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: SKIN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SKIN is expected to become profitable in the next 3 years.
Revenue vs Market: SKIN's revenue (5.1% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: SKIN's revenue (5.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SKIN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 20:06 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
The Beauty Health Company is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Navann Ty Dietschi | BNP Paribas Exane |
| Kyle Rose | Canaccord Genuity |